Additional applications of corneal cross linking
- PMID: 21448300
- PMCID: PMC3065117
- DOI: 10.2174/1874364101105010017
Additional applications of corneal cross linking
Abstract
Corneal collagen cross-linking (CxL) is a prevalent surgical method for the management of keratoconus. However, literature suggests that, further to keratoconus, CxL has a beneficial impact on a series of corneal related diseases and states. This article attempts to provide a contemporary review for all additional applications of CxL. Specifically, it outlines the most recent studies that demonstrate the beneficial impact of CxL for iatrogenic ectasias, pellucid marginal degeneration, infectious keratitis, bullous keratitopathy, and for ulcerative keratitis. The outcome of this review indicates that CxL could serve as a primary or adjuvant therapeutic modality for all aforementioned corneal-related pathologic states.
Keywords: Corneal collagen cross-linking; bullous keratopathy; iatrogenic ectasias; infectious keratitis.; pellucid marginal degeneration; review.
References
-
- Hafezi F, Kanellopoulos J, Wiltfang R, Seiler T. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after LASIK. J Cataract Refract Surg. 2007;33(12 ):2035–40. - PubMed
-
- Kymionis GD, Karavitaki AE, Kounis GA, et al. Management of pellucid marginal corneal degeneration with simultaneous customized photorefractive keratectomy and collagen crosslinking. J Cataract Refract Surg. 2009;35(7):1298–301. - PubMed
-
- Wollensak G, Aurich H, Wirbelauer C, Pham DT. Potential use of Riboflavin/ UVA crosslinking in bullous keratopathy. Ophthalmic Res. 2009;41(2):114–7. - PubMed
-
- Krueger RR, Ramos-Esteban JC, Kanellopoulos AJ. Staged intrastromal delivery of riboflavin with UVA cross-linking in advanced bullous keratopathy: laboratory investigation and first clinical case. J Refract Surg. 2008;24(7 ):S730–6. - PubMed
-
- Martins SAR, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 n). In vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49:3402–8. - PubMed
LinkOut - more resources
Full Text Sources